HANGZHOU, China and SHAOXING, China, Aug. 16, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase...
from PR Newswire: https://ift.tt/3kPrzL2
No comments:
Post a Comment